Protalix BioTherapeutics (NYSE:PLX) Posts Earnings Results, Misses Estimates By $0.05 EPS

Protalix BioTherapeutics (NYSE:PLX) released its earnings results on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.05), RTT News reports. Protalix BioTherapeutics had a return on equity of 19.48% and a net margin of 11.48%. The firm had revenue of $13.47 million during the quarter, compared to analysts’ expectations of $12.50 million. During the same period in the prior year, the company posted ($0.07) earnings per share.

Protalix BioTherapeutics Stock Performance

Shares of PLX traded up $0.05 during mid-day trading on Thursday, reaching $0.98. The stock had a trading volume of 180,302 shares, compared to its average volume of 393,976. The business has a fifty day moving average of $1.12 and a 200 day moving average of $1.24. The firm has a market cap of $71.91 million, a price-to-earnings ratio of 23.25 and a beta of 0.78. Protalix BioTherapeutics has a 12 month low of $0.82 and a 12 month high of $2.06.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.